MedTrace Logo

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

NCT00282282 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2014-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell transplantation.

Conditions

Interventions

DRUG

tacrolimus

Given orally just prior to and following stem cell transplant

DRUG

sirolimus

Given orally just prior to and following stem cell transplant

DRUG

fludarabine

Given once daily over 30 minutes for 4 days

DRUG

busulfex

Given intravenously over 3 hours for 4 days

Sponsors & Collaborators

Principal Investigators

  • Vincent Ho, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-01-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282282 on ClinicalTrials.gov